Wellington Management Group LLP Purchases Shares of 463,192 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Wellington Management Group LLP acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 463,192 shares of the company’s stock, valued at approximately $931,000. Wellington Management Group LLP owned 0.23% of Taysha Gene Therapies as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Creative Planning acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at approximately $28,000. Principal Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies in the second quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its position in Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after acquiring an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at $85,000. Finally, Scientech Research LLC bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $97,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $1.85 on Friday. The business has a 50 day simple moving average of $2.14 and a 200 day simple moving average of $2.32. Taysha Gene Therapies, Inc. has a one year low of $1.19 and a one year high of $4.32. The company has a market capitalization of $379.14 million, a PE ratio of 2.94 and a beta of 0.79. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Wall Street Analysts Forecast Growth

TSHA has been the topic of several research reports. Chardan Capital restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Finally, Canaccord Genuity Group upped their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.